Pharmacodynamic Analysis of Daptomycin-treated Enterococcal Bacteremia: It Is Time to Change the Breakpoint

M. Avery, Lindsay; L. Kuti, Joseph; Weisser, Maja; Egli, Adrian; J. Rybak, Michael; J Zasowski, Evan; A. Arias, César; Contreras, German; P. Chong, Pearlie; L Aitken, Samuel; J. DiPippo, Adam; Wang, Jann‐Tay; Britt, Nicholas; P. Nicolau, David

doi:10.1093/cid/ciy749

Public

Pharmacodynamic Analysis of Daptomycin-treated Enterococcal Bacteremia: It Is Time to Change the Breakpoint

Published in Clinical Infectious Diseases • Aug 29, 2018

Authors:

Lindsay M. Avery

Joseph L. Kuti

Maja Weisser

Abstract

BACKGROUND: Currently, there is debate over whether the daptomycin susceptibility breakpoint for enterococci (ie, minimum inhibitory concentration [MIC] ≤4 mg/L) is appropriate. In bacteremia, observational data support prescription of high doses (>8 mg/kg). However, pharmacodynamic targets associat...

Subject

Daptomycin

Medicine

Bacteremia

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!